Biologics are transforming medicine, but who’s enabling that transformation behind the scenes? In this episode, I sit down with Jiri Raska, Chief Commercial Officer at Quinta Analytica, and Pavlina Walter, to discuss:

• Why biologics and biosimilars are now the fastest-growing segment in pharma

• How CROs are evolving from vendors to strategic partners

• What small biotechs need most to reach clinical milestones

• Europe’s regulatory turnaround under the new CTIS system

• The rise of ADCs and how integrated analytics create real competitive advantage
  

Timecode:

00:00 Introduction to Jiri and Quinta Analytica

01:09 Jiri's Background and Passion for Chemistry

01:56 Transition to Business Development

03:43 Current Trends in Biologics and Biosimilars

05:57 Challenges and Opportunities in Clinical Studies

09:17 Supporting Small Biotech Startups

13:08 Customer Success Management

14:47 Expansion and Collaboration

16:43 Future of Personalized Medicine

19:26 Regulatory Challenges in Europe

23:58 Ostrava Subsidiary and Cross-Border Recruitment

27:00 Future Directions for Quinta Analytica

29:50 Jiri's Personal Career Aspirations

31:49 Conclusion and Final Thoughts

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Jiri Raska: https://www.linkedin.com/in/jiri-raska-pharma/

Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/

In this episode of Clinical Capital Conversations, I sat down with Pavlina Walter and our guest Jiri Pavlíček, a mentor, entrepreneur, and one of Central Europe’s most respected MedTech leaders. Together, we explored everything from the European MedTech landscape to AI-driven diagnostics, MDR regulation, and the importance of risk-taking culture. 

From navigating post-Communist transitions to leading a multi-market MedTech enterprise and embracing AI-driven technologies, Jiri’s story reveals what it takes to combine operational excellence with human-centered values.

Key themes:

• Leadership and values in healthcare innovation

• European MedTech market outlook and MDR challenges

• AI as the next wave in diagnostics

• Building teams and trust that scale

• Resilience, mindset, and long-term impact
  

Timecode:

00:00 Welcome and Introduction

00:28 Jiri's Background and Early Life

01:26 Professional Journey and Achievements

03:49 Founding Aspironix and Business Insights

06:05 Current MedTech Landscape and Challenges

11:58 AI in Medical Devices

14:19 Personal Reflections and Future Goals

17:04 Advice for Startups and Entrepreneurs

19:29 Closing Remarks

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Jiri Pavlicek: https://www.linkedin.com/in/jiri-pavlicek-7b32b12/

Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/

In this episode, Peter M. Kovacs speaks with Károly Szántó and Thijmen Meijer, co-founders of Uniprisma, about how Central Europe’s startup scene is maturing from ideas to execution.

They discuss founder psychology, team readiness, ego management, and why venture studios are redefining early-stage investment across Europe.

Chapters

00:00  Introduction and context

01:10  What Uniprisma is and how it started

05:30  Why founder personality defines success

09:15  When to replace the founder as CEO

14:20  Building high-performance startup teams

18:40  The biggest mistakes in early-stage ventures

23:00  Teaching founders to engage markets early

28:15  Investor perspective on people vs products

33:30  The YON E Health case and early success stories

38:50  How venture studios de-risk early investment

44:00  Central Europe’s innovation potential

49:30  Final reflections

If you invest in early-stage ventures or build founder support ecosystems, watch this conversation to understand how execution discipline is becoming Central Europe’s competitive edge.

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Károly Szántó: https://www.linkedin.com/in/karolyszanto1/

Thijmen Meijer: https://www.linkedin.com/in/thmnmr/

In this episode, Peter M. Kovacs speaks with Roswitha Verwer and Dr. Muskaan Bhan, the founders of YON E Health, about transforming personal trauma into global innovation. They discuss the journey from idea to clinical-grade Femtech, data ethics, diversity in research, and why women’s health is the next major frontier for investors and operators alike.

Chapters

00:00  Introduction and context

01:15  How Roswitha and Muskaan met

04:30  The personal story behind YON E Health

08:10  What pH and temperature tell us about women’s health

12:25  Building a medical device from concept to clinical validation

18:40  Why diversity in clinical data matters

23:00  Regulatory roadmap and CE/FDA pathway

27:30  Investment challenges for female founders

33:00  Data privacy, consent, and trust

39:45  Culture, education, and global adoption

45:20  Team building and advisory governance

52:10  The future of Femtech and Peter’s reflections

If you are investing in healthcare or building within Femtech, watch this discussion to understand why precision, transparency, and inclusion are the new performance metrics.

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital.

What will decide the future of AI in Europe: ethics, bureaucracy, or competitiveness?

In this episode, I sit down with Jan Kavalírek, Deputy Minister of Industry and Trade and Government Envoy for AI in the Czech Republic, together with Pavlina Walter, to discuss:

• Why Czechia was the first EU country to propose AI simplification.

• How regulation can protect safety without paralysing innovation.

• What Europe must do to close the gap with the US and China.

• The role of startups and SMEs in building a competitive AI ecosystem.

• Why AI policy directly impacts healthcare, clinical research, and patient outcomes.
  

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital.

Timecode:

00:00 Introduction to Jan Kavalirek and His Role

00:52 Goals and Ambitions for AI in Czechia and EU

01:38 Simplifying AI Legislation in the EU

03:16 Challenges and Support for AI Providers

07:05 Collaboration and Competitiveness in AI

12:25 Personal Reflections and Experiences

18:10 Future Prospects and Conclusion

Links:

Jan Kavalírek : linkedin.com/in/jan-kavalirek-339a1a298

Pavlina Walter: https://www.linkedin.com/in/pavlinawalter/

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Who We Are: PMK Group and Our Mission in Biotech | Clinical Capital Conversations

Biotech often fails for the wrong reasons. Nearly 60% of clinical trial failures are due to technical execution, not the science itself.

In this episode, Dr. Peter M. Kovacs explains why he founded PMK Group, a firm that combines capital with clinical and regulatory expertise to reduce technical failures and accelerate drug development.

Why it matters:

– Billions are lost to preventable execution failures

– Patients wait years for therapies that could be delivered faster

– Investors face unnecessary downside risk

PMK Group’s model is different: we do not just invest money. We invest experience, systems, and execution.

Subscribe to Clinical Capital Conversations for more insights at the crossroads of science and capital.

Timecode:

00:00 Introduction to Success in Biotech

00:16 Understanding the Main Risks in Biotech

00:44 Meet the Leader: Peter M. Kovacs

01:06 The PMK Group Difference

01:42 Minimizing Technical Failures

02:09 Supporting Biotech and MedTech Companies

02:32 Vision for the Future

02:58 Call to Collaborate

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

What does real AI adoption in healthcare look like when you leave the hype behind?

In this Prague Episode, I speak with Lukas Benzel, Managing Director of the Czech Association of Artificial Intelligence, and Pavlina Walter. We cover hospital adoption, the shift from sick care to prevention, the role of AI in clinical trials, Europe’s strategic approach, and why Singapore’s model is significant. Practical playbooks for investors, founders, and operators.

Chapters

00:00 Welcome and context in Prague

00:35 Who is the Czech AI Association and why it matters

02:10 Hype vs value in AI adoption

04:05 Workshops, education, and finding business value

05:10 Sectors with traction: healthcare, education, defense, public sector

06:20 Health tech in Czech hospitals and regulation reality

07:55 Europe, US, and Asia: where to compete

09:10 Singapore lessons and the AI hub model 12:05 Constraints in hospitals: money, people, data readiness

13:00 Beyond radiology: prevention, trials, and operations

15:10 Patient acceptance, trust, and education

18:05 National AI strategy and public sector adoption

20:05 From basic research to new materials and drugs

21:30 AI for SMEs: pick use cases with ROI

23:00 Is AI a bubble. Why the answer is no

24:15 Productivity, new work, and personal tools

28:40 Cybersecurity and responsible use

31:00 Why an AI association, how to join

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

In this episode, Dr. Peter M. Kovacs shares the story of how a study trip in 2018 transformed his life.

Within weeks, he decided to relocate his family to Singapore, a country that would become both his home and the strategic hub for his global healthcare and investment ventures.

Why Singapore?

A clean, safe, efficient environment

A business, biotech, and financial hub

Access to Asia’s fast-growing healthcare markets

Supportive policies and an innovation-friendly culture

This is more than a relocation story. It’s about resilience, vision, and what it means to position yourself at the heart of the world’s most dynamic region.

Timecode:

00:00 Why and How I Moved to Singapore

00:04 Starting My Healthcare MBA Journey

00:56 Discovering Singapore

01:27 Making the Move Permanent

01:45 Professional and Personal Benefits of Singapore

02:07 Expanding into the Asian Market

03:20 Singapore: The Ideal Business Hub

Links:

LinkedIn: https://www.linkedin.com/in/petermkovacs/

PMK Group Website: https://www.pmk-group.com/

Peter M. Kovacs Personal Website: https://www.petermkovacs.com/